Zacks Research Brokers Reduce Earnings Estimates for VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Zacks Research lowered their Q2 2027 earnings per share (EPS) estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Monday, November 24th. Zacks Research analyst Team now anticipates that the pharmaceutical company will post earnings per share of $4.45 for the quarter, down from their prior forecast of $4.60. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Several other research firms have also recently issued reports on VRTX. Scotiabank began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $495.00 price objective for the company. Guggenheim lowered their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. BMO Capital Markets set a $530.00 price objective on Vertex Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, August 5th. Royal Bank Of Canada decreased their target price on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 4th. Finally, Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $491.95.

Vertex Pharmaceuticals Stock Up 0.5%

NASDAQ VRTX opened at $432.17 on Wednesday. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $519.68. The firm has a 50 day moving average of $413.68 and a two-hundred day moving average of $425.04. The stock has a market capitalization of $109.65 billion, a PE ratio of 30.89 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the company posted $4.38 earnings per share. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 53,604 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $440.72, for a total transaction of $23,624,354.88. Following the transaction, the chairman directly owned 24,026 shares in the company, valued at approximately $10,588,738.72. This trade represents a 69.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

Large investors have recently bought and sold shares of the business. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd lifted its position in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares during the period. Access Investment Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $27,000. Chesapeake Asset Management LLC grew its stake in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 33 shares during the last quarter. Finally, Flaharty Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth approximately $32,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.